← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Manzanita Pharmaceuticals, Inc.
Woodside, CA
$4,257,704
Total funding
3
Grants
Funding over time
peak $1.2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,257,704 · 3
By mechanism
R44$3,969,403 · 2
R43$288,301 · 1
Investigators at Manzanita Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent$1,220,153
R44 · FY2017 · CA
Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer$1,090,970
R44 · FY2025 · CA
Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer$905,526
R44 · FY2024 · CA
Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent$752,754
R44 · FY2018 · CA
In vivo feasibility of a peripheral nerve imaging agent$288,301
R43 · FY2013 · CA